Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin
(CBDCA) as first line treatment in advenced non-small lung
cancer (NSCLC) patients: results of a prospective study in
nonrandomized and unselected population of 396 patient

a 2013

Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient

SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ et. al.

Základní údaje

Originální název

Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient

Autoři

Vydání

15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia, 2013

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30203 Respiratory systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.800

Organizační jednotka

Lékařská fakulta

ISSN

Klíčová slova anglicky

first-line treatment; NSCLC

Změněno: 28. 2. 2014 17:07, Soňa Böhmová

Anotace

V originále

In this group of 396 unselected patients with advanced NSCLC was the treatment with full NVBO and-CBDCA in first line more convenient and well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology (mOS was 9,92 and mPFS was 7,4 months). Statistically significant better were the results in patients with PS 0+1.

Citovat

SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ, Vítězslav KOLEK, Ivona GRYGÁRKOVÁ, Helena ČOUPKOVÁ, Jiří CHALUPA, Jiří BARTOŠ, Pavel REITERER a Milada ZEMANOVÁ. Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient. In 15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia. 2013. ISSN 1556-0864.

@proceedings{1136258,
   author = {Skřičková, Jana and Kadlec, Bohdan and Venclíček, Ondřej and Jakubíková, Lenka and Janásková, Tereza and Kolek, Vítězslav and Grygárková, Ivona and Čoupková, Helena and Chalupa, Jiří and Bartoš, Jiří and Reiterer, Pavel and Zemanová, Milada},
   booktitle = {15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia},
   keywords = {first-line treatment; NSCLC},
   language = {eng},
   title = {Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient},
   year = {2013}
}

TY  - CONF
ID  - 1136258
AU  - Skřičková, Jana - Kadlec, Bohdan - Venclíček, Ondřej - Jakubíková, Lenka - Janásková, Tereza - Kolek, Vítězslav - Grygárková, Ivona - Čoupková, Helena - Chalupa, Jiří - Bartoš, Jiří - Reiterer, Pavel - Zemanová, Milada
PY  - 2013
TI  - Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient
KW  - first-line treatment
KW  - NSCLC
N2  - In this group of 396 unselected patients with advanced NSCLC was the treatment with full NVBO and-CBDCA in first line more convenient and well tolerated with evidence of high antitumour activity. This combination was active in all groups patients according histology (mOS was 9,92 and mPFS was 7,4 months). Statistically significant better were the results in patients with PS 0+1.
ER  -

SKŘIČKOVÁ, Jana, Bohdan KADLEC, Ondřej VENCLÍČEK, Lenka JAKUBÍKOVÁ, Tereza JANÁSKOVÁ, Vítězslav KOLEK, Ivona GRYGÁRKOVÁ, Helena ČOUPKOVÁ, Jiří CHALUPA, Jiří BARTOŠ, Pavel REITERER a Milada ZEMANOVÁ. Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advenced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient. In \textit{15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia}. 2013. ISSN~1556-0864.

Přehled o publikaci